cytarabine has been researched along with tosedostat in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Burnett, A; Hewamana, S; Jenkins, C; Krige, D; Pepper, C | 1 |
| Advani, AS; Charman, A; Cortes, J; Feldman, E; Kantarjian, H; Rizzieri, D; Spruyt, R; Toal, M; Yee, K | 1 |
| Becker, PS; Dean, C; Deeg, HJ; Estey, E; Hendrie, P; Mawad, R; Myint, H; Pagel, JM; Sandhu, V; Scott, B; Singer, JW; Walter, R; Wang, L; Wood, BL | 1 |
| Candoni, A; Clavio, M; Dennis, M; Giannini, B; Gibellini, D; Gilkes, A; Isidori, A; Loscocco, F; Mianulli, AM; Musuraca, G; Navari, M; Piccaluga, PP; Rocchi, M; Sensi, A; Visani, G; Zuffa, E | 1 |
| Ariti, C; Burnett, A; Clark, RE; Copland, M; Dennis, M; Greaves, P; Hemmaway, C; Hills, R; Russell, N; Severinsen, MT; Thomas, I | 1 |
3 trial(s) available for cytarabine and tosedostat
| Article | Year |
|---|---|
Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study.
Topics: Aged; Aged, 80 and over; Anemia, Refractory; Cytarabine; Disease-Free Survival; Female; Glycine; Humans; Hydroxamic Acids; Leukemia, Monocytic, Acute; Male; Middle Aged; Recurrence; Remission Induction | 2013 |
Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Female; Glycine; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Survival Analysis; Treatment Outcome | 2016 |
A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Enzyme Inhibitors; Female; Glycine; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Analysis | 2021 |
2 other study(ies) available for cytarabine and tosedostat
| Article | Year |
|---|---|
Aminopeptidase inhibition by the novel agent CHR-2797 (tosedostat) for the therapy of acute myeloid leukemia.
Topics: Adult; Aminopeptidases; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Culture Techniques; Cytarabine; Drug Evaluation, Preclinical; Enzyme Inhibitors; Female; Glycine; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Male; Middle Aged; Tumor Cells, Cultured; Young Adult | 2011 |
Gene expression profile predicts response to the combination of tosedostat and low-dose cytarabine in elderly AML.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Glycine; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Microarray Analysis; Transcriptome | 2020 |